|
| Monday, December 15, 2025 |
|
|
Everest Medicines Unveils 2030 Strategy as Directors and Substantial Shareholder Buy Over HKD 38 Million of Shares |
| Everest Medicines (HKEX: 1952.HK) today unveiled its 2030 strategy. Following the announcement, the Company's shares strengthened during the trading session and briefly reached an intraday high of HKD 48.54. more info >> |
|
| Friday, December 12, 2025 |
|
|
Everest Medicines Announces Commercialization Service Agreement and License Agreement with Hasten |
| Everest Medicines announced on Dec. 11, 2025 that its wholly-owned subsidiary, Everest Medicines (China) Co., Ltd ('Everest Medicines China'), has entered into two strategic agreements with privately held Hasten Biopharmaceutical Co., Ltd. ('Hasten'). more info >> |
|
| Thursday, October 30, 2025 |
|
|
Everest Medicines Acquires Exclusive Greater China and Other Asian Country Rights to VIS-101, a Novel Bifunctional Biologic for Serious Eye Disorders |
| Everest Medicines (HKEX:1952.HK) today announced that it has acquired an exclusive license with Visara, Inc. ('Visara'), a subsidiary of NovaBridge Biosciences (formally known as I-Mab, and is a company listed on the Nasdaq Global Market trading under the symbol 'NBP'), to secure an exclusive license to develop, manufacture and commercialize VIS-101, in Greater China, Singapore, South Korea and certain Southeast Asian countries. more info >> |
|
| Tuesday, October 14, 2025 |
|
|
Everest Medicines Announces First Patient Enrolled in a Global Multi-Center Phase I Clinical Trial of Tumor-Associated Antigen Cancer Vaccine EVM14 |
| Everest Medicines today announced that the first patient has been enrolled in a global multi-center Phase I clinical trial of its Tumor-Associated Antigen Cancer Vaccine EVM14 at NEXT Oncology Virginia in the United States. more info >> |
|
| Thursday, October 9, 2025 |
|
|
Everest Medicines Announces Publication of Etrasimod's Asian Multicenter Phase III ENLIGHT UC study (ES101002) Results in The Lancet Gastroenterology & Hepatology |
| Everest Medicines today announced that the results of its Asian multicenter Phase III ENLIGHT UC study (ES101002) of etrasimod (VELSIPITY(R)) for the treatment of subjects with moderately to severely active ulcerative colitis (UC) have been published in the prestigious international journal The Lancet Gastroenterology & Hepatology, marking the global recognition of this next-generation selective S1P receptor modulator's efficacy in Asian patients. more info >> |
|
| Monday, September 1, 2025 |
|
|
Everest Medicines Announces 2025 Interim Results: 'Dual-Engine' Strategy Driving Strong Synergies Between Commercialization and R&D |
| Everest Medicines (1952.HK) announced its interim results for the six months ended June 30, 2025. The Company's total revenue for the first half of 2025 reached RMB 446 million, representing 48% year-over-year growth, while operating expenses as a percentage of revenue decreased by 40.1 percentage points, reflecting strong operational efficiency. more info >> |
|
| Friday, August 15, 2025 |
|
|
Etrasimod Receives Strong Recommendation in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults for Induction and Maintenance Phase of Moderately to Severely Active UC |
| Everest Medicines today announced that etrasimod (VELSIPITY(R)) has been included in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults (the 'Updated Guidelines'). Etrasimod, an S1P receptor modulator, is recommended for the induction of remission in patients with moderately to severely active UC and for continuation in the maintenance of remission, compared with no treatment after induction of remission. Both recommendations are strong, with a moderate quality of evidence. more info >> |
|
| Thursday, August 14, 2025 |
|
|
Everest Medicines' New Drug Application for Etrasimod Accepted in Taiwan, Marking Another Milestone in Asia Market Access |
| Everest Medicines (HKEX 1952.HK, 'Everest') today announced that the Taiwan Food and Drug Administration (TFDA) has officially accepted the New Drug Application (NDA) for VELSIPITY' (etrasimod) for the treatment of patients with moderately to severely active ulcerative colitis (UC). more info >> |
|
| Friday, August 8, 2025 |
|
|
Everest Medicines Announces Full Approval of NEFECON(R) in Taiwan |
| Everest Medicines (HKEX 1952.HK) recently announced the Taiwan Food and Drug Administration (TFDA) has approved the supplementary application for NEFECON'. more info >> |
|
| Tuesday, August 5, 2025 |
|
|
NEFECON(R) Receives NMPA Approval for Production Expansion in China, as Everest Medicines Accelerates Accessibility and Capacity Efforts |
| Everest Medicines (HKEX 1952.HK) today announced that the supplemental application for the production expansion of NEFECON has been officially approved by China's National Medical Products Administration (NMPA). more info >> |
|
|
|
